LoadingLoadingLoadingThe quick read
Latest quote·Oct 15
Net buying: insiders sold $83K and bought $3M on the open market in 90 days (SEC Form 4). Congress: net selling of $15K to $50K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet buying: insiders sold $83K and bought $3M of PFE stock on the open market in the 90 days to Oct 16, 2026, according to SEC Form 4 filings. The largest was Bourla, Albert (Chairman & CEO), who bought $1M. The latest filing was on Aug 12, 2026.
Sen. Thomas H Tuberville (R) sold $15K to $50K on Jun 8, 2026, disclosed 38 days later. In total, 1 member disclosed 1 PFE trade with trade dates in the last 180 days, filed a median 38 days after trading.
This summary uses filings available on Oct 16, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net buying.
Buys/Adds (1)
Susquehanna
$124.4M
added
Sells/Trims (2)
Balyasny
$273.4M
trimmed
D.E. Shaw
$219.7M
trimmed
Buys (2)
Bourla Albert
$1.0M
bought
Blaylock Ronald E
$999K
bought
Sells (1)
Damico Jennifer B.
$83K
sold
No tracked top-trader positions in PFE right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Aug 4, 2026
Financial period
Q2 2026
Adjusted EPS
$0.68 expected
Revenue
$14.39B expected
FY2026 guidance
$60.50B to $62.50B
No comparable estimate
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | $0.77 / $0.68Yahoo Finance | +12.87% beat | $15.03B / $14.39B | +4.49% beat |
| Mar 31, 2026 | May 5, 2026 | $0.75 / $0.72Yahoo Finance | +3.93% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 3, 2026 | $0.66 / $0.57Yahoo Finance | +16.18% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 4, 2025 | $0.87 / $0.63Yahoo Finance | +37.43% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 5, 2025 | $0.78 / $0.57Alpha Vantage | +36.84% beat | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 29, 2025 | $0.92 / $0.67Alpha Vantage | +37.31% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 4, 2025 | $0.63 / $0.46Alpha Vantage | +36.96% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 29, 2024 | $1.06 / $0.61Alpha Vantage | +73.77% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 16, 2026
EPS expected
$0.59 to $0.94
Revenue expected
16 analysts
Last 30 days
Analysts cutting estimates
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $16.65B | $17.56B | $14.45B | $15.03B |
| Cost of what it sold | $4.17B | $5.27B | $4.73B | $4.09B |
| Gross profit | $12.48B | $12.29B | $9.72B | $10.94B |
| What it spent | ||||
| Research and development | $3.94B | $3.42B | $2.63B | $2.81B |
| Sales and admin | $3.19B | $4.08B | $2.96B | $3.41B |
| Other operating costs | $1.81B | $1.10B | $100.0M | — |
| Total operating expenses | $8.93B | $8.60B | $5.69B | $6.24B |
| What was left | ||||
| Operating profit | $3.55B | $3.69B | $4.03B | $4.71B |
| Interest on debt | $652.0M | $711.0M | $668.0M | $667.0M |
| Profit before tax | $3.33B | -$1.64B | $3.17B | -$653.0M |
| Tax | -$216.0M | -$2.0M | $461.0M | -$407.0M |
| Net profit | $3.54B | -$1.65B | $2.69B | -$246.0M |
| EBITDA | $5.65B | $756.0M | $5.45B | $1.64B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Pfizer (PFE) Could Be 60% Below Fair Value On Tukysa Approval And Vaccine Data
Leans bullishOct 15Perpetual Ltd Sells 1,598 Shares of Regeneron Pharmaceuticals, Inc. $REGN
NeutralOct 15Valneva to present Lyme vaccine updates at US and European investor conferences
Leans bullishOct 15Pfizer Inc (Coinbase Tokenized Stock) Price | PFEc Price Today, Live Chart, USD converter, Market Capitalization
NeutralOct 14Pfizer (PFE) Gains As Market Dips: What You Should Know
Leans bullishOct 14Better High-Yield Dividend Stock: Pfizer vs. British American Tobacco
NeutralOct 14Micro Pfizer Inc Stock Futures, (XPFE0Z26.CME) Stock Historical Prices & Data - Yahoo Finance
Leans bullishOct 14Does Unusual Options Trading Change The Bull Case For Innoviva Stock (INVA)?
Leans bullishOct 14